CN101647793A - Application of anacardic acid in preparing anti-angiogenic drugs - Google Patents
Application of anacardic acid in preparing anti-angiogenic drugs Download PDFInfo
- Publication number
- CN101647793A CN101647793A CN200910056246A CN200910056246A CN101647793A CN 101647793 A CN101647793 A CN 101647793A CN 200910056246 A CN200910056246 A CN 200910056246A CN 200910056246 A CN200910056246 A CN 200910056246A CN 101647793 A CN101647793 A CN 101647793A
- Authority
- CN
- China
- Prior art keywords
- angiogenesis
- anacardic acid
- blood vessel
- angiogenic drugs
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000014398 anacardic acid Nutrition 0.000 title claims abstract description 54
- KAOMOVYHGLSFHQ-UTOQUPLUSA-N anacardic acid Chemical compound CCC\C=C/C\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O KAOMOVYHGLSFHQ-UTOQUPLUSA-N 0.000 title claims abstract description 53
- ADFWQBGTDJIESE-UHFFFAOYSA-N anacardic acid 15:0 Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O ADFWQBGTDJIESE-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 239000004037 angiogenesis inhibitor Substances 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 230000033115 angiogenesis Effects 0.000 claims abstract description 22
- 230000001575 pathological effect Effects 0.000 claims abstract description 9
- 201000011066 hemangioma Diseases 0.000 claims abstract description 7
- 208000030533 eye disease Diseases 0.000 claims abstract description 6
- 206010003246 arthritis Diseases 0.000 claims abstract description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims abstract description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 3
- 208000027868 Paget disease Diseases 0.000 claims abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 3
- 201000005787 hematologic cancer Diseases 0.000 claims abstract description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 231100000915 pathological change Toxicity 0.000 claims description 6
- 230000036285 pathological change Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000000252 angiomatosis Diseases 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 206010023365 keratopathy Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000001185 psoriatic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
- 210000003606 umbilical vein Anatomy 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 210000002889 endothelial cell Anatomy 0.000 description 20
- 239000003814 drug Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003725 endotheliocyte Anatomy 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 5
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000002687 Caesalpinia echinata Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000127464 Paubrasilia echinata Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023343 iris disease Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- -1 tetrazole compound Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910056246XA CN101647793B (en) | 2009-08-11 | 2009-08-11 | Application of anacardic acid in preparing anti-angiogenic drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910056246XA CN101647793B (en) | 2009-08-11 | 2009-08-11 | Application of anacardic acid in preparing anti-angiogenic drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101647793A true CN101647793A (en) | 2010-02-17 |
CN101647793B CN101647793B (en) | 2011-06-29 |
Family
ID=41670191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910056246XA Expired - Fee Related CN101647793B (en) | 2009-08-11 | 2009-08-11 | Application of anacardic acid in preparing anti-angiogenic drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101647793B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111420059A (en) * | 2020-01-10 | 2020-07-17 | 中山大学 | Medicine composition for overcoming drug resistance of liver cancer and kidney cancer tumors and application thereof |
-
2009
- 2009-08-11 CN CN200910056246XA patent/CN101647793B/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111420059A (en) * | 2020-01-10 | 2020-07-17 | 中山大学 | Medicine composition for overcoming drug resistance of liver cancer and kidney cancer tumors and application thereof |
CN111420059B (en) * | 2020-01-10 | 2021-09-24 | 中山大学 | Medicine composition for overcoming drug resistance of liver cancer and kidney cancer tumors and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101647793B (en) | 2011-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101647801A (en) | Application of tetracyclic triterpenoids compound in preparing anti-angiogenic drugs | |
CN108159038A (en) | A kind of pharmaceutical composition and its purposes in the drug for preparing treatment multi-drug resistance of the tumor | |
CN101647796A (en) | Application of osthole in preparing anti-angiogenic drugs | |
CN100522184C (en) | Extract with anti-tumor and anti-poisonous activity | |
CN102048727B (en) | Application of formononetin in preparing of medicament for restricting angiogenesis | |
CN102166260B (en) | Clove extract with tumor resisting effect and pharmaceutical preparation thereof | |
CN101647793B (en) | Application of anacardic acid in preparing anti-angiogenic drugs | |
CN104490942B (en) | Phellinus igniarius (L. ex Fr.) Quel. is as the application of tumor | |
CN101597324A (en) | A kind of decapeptide inhibiting angiogenesis and application thereof | |
CN101434648A (en) | Peptide for inhibiting angiogenesis, and use thereof in angiogenesis medicament preparation | |
CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
CN101278925A (en) | Application of embellin in preparation of medicament for inhibiting angiogenesis | |
CN106955292A (en) | A kind of pharmaceutical composition and purposes for treating the cancer of the esophagus | |
CN101664401A (en) | Application of usnic acid in preparation of drugs inhibiting angiogenesis | |
CN103127061A (en) | Medicine application of chloranthus japonicus alcohol M | |
CN103417536B (en) | The application in antitumor drug prepared by harmol | |
CN105560224A (en) | Application of salinomycin to preparation of angiogenesis inhibiting medicine | |
CN101283994A (en) | Application of plumbagin in preparing the medicine for preventing the blood vessel from regenerating | |
CN108904510A (en) | Dexamethasone is used to inhibit or treat the purposes of cancer of pancreas | |
CN108096239A (en) | A kind of pharmaceutical composition for treating glioma and liver cancer | |
CN102133219A (en) | Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof | |
CN102309487A (en) | The antihepatocarcinoma effect of piperine and pharmaceutical preparation thereof | |
CN102579419A (en) | Novel anticancer application of chlorogenic acid | |
CN107693509A (en) | SB FI 26 are preparing the application in treating breast cancer medicines | |
CN102151275A (en) | Pancreatic cancer-resisting effect of oleanolic acid and pharmaceutical preparation of oleanolic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160229 Address after: 201100. A2114, building B, building 555, Dongchuan Road, Minhang District, Shanghai Patentee after: BIORAY LABORATORIES Inc. Address before: 200062 Zhongshan North Road, Shanghai, No. 3663 Patentee before: East China Normal University |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of lacquer tree acid in the preparation of anti angiogenesis drugs Effective date of registration: 20211228 Granted publication date: 20110629 Pledgee: Minhang Branch of Shanghai Rural Commercial Bank Co.,Ltd. Pledgor: BIORAY LABORATORIES Inc. Registration number: Y2021310000165 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220826 Granted publication date: 20110629 Pledgee: Minhang Branch of Shanghai Rural Commercial Bank Co.,Ltd. Pledgor: BIORAY LABORATORIES Inc. Registration number: Y2021310000165 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110629 |